S-1 maintenance therapy after surgery for high-risk pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether taking an oral chemotherapy pill called S-1 after standard treatment can help prevent pancreatic cancer from coming back in people whose cancer had high-risk features. If you qualify, you would take S-1 for a period of time instead of just being watched.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had pancreatic cancer that started in the ducts of the pancreas.
- Your cancer had high-risk features (like being poorly differentiated, spread to lymph nodes, or a positive margin after surgery).
- You already completed standard chemotherapy (and possibly radiation) after your surgery.
- You are able to take pills by mouth.
- Your blood counts and liver/kidney function are within acceptable ranges.
- You are between 18 and 75 years old and in generally good health (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.